| Drug Name |
Etanercept |
| Drug ID |
BADD_D00838 |
| Description |
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). |
| Indications and Usage |
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AB01 |
| DrugBank ID |
DB00005
|
| KEGG ID |
D00742
|
| MeSH ID |
D000068800
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0I5QX
|
| NDC Product Code |
58406-044; 58406-055; 58406-032; 58406-010; 58406-021; 58406-425; 58406-446; 58406-435; 58406-455; 58406-445; 58406-456 |
| UNII |
OP401G7OJC
|
| Synonyms |
Etanercept | TNFR-Fc Fusion Protein | Fusion Protein, TNFR-Fc | TNFR Fc Fusion Protein | TNR 001 | TNT Receptor Fusion Protein | TNTR-Fc | TNR-001 | TNR001 | Etanercept-szzs | TNF Receptor Type II-IgG Fusion Protein | TNF Receptor Type II IgG Fusion Protein | Erelzi | Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein | Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein | Enbrel |
